Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
mesothelioma/nausée
Le lien est enregistré dans le presse-papiers
Page 1 de 125 résultats
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naïve pleural mesothelioma.
METHODS
Eligible patients had a histologic or cytologic diagnosis of
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Twenty-five patients with histologically proven malignant mesothelioma participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400 mg per day taken orally, up to a maximal dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (>6
A phase II study of pirarubicin in malignant pleural mesothelioma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The treatment was repeated every 3 to 4 weeks (median
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
We performed a phase-II-study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i. e., ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for
A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
A total of 29 previously untreated patients with histologically proven malignant pleural mesothelioma, with an ECOG score of < or = 2 and UICC stage I-II disease, were enrolled between May 1994 and October 1996. On days 1 and 2, 18 x 10(6) IU/day of rIL-2 was administered by continuous intravenous
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m2 on days 1, 3 and 5 every 3 weeks. The second trial
Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Diffuse malignant peritoneal mesotheliomas in children are uncommon, aggressive tumors with a grave prognosis. We herein report the clinical, radiologic, and pathologic findings of a 16-year-old male. The adolescent presented with a history of abdominal pain, nausea and daily, nonbilious, nonbloody
Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVE
The combination of chemotherapy, surgery, and radiotherapy has improved the prognosis for patients with malignant pleural mesothelioma (MPM). Intensity-modulated radiotherapy (IMRT) has allowed for an increase in dose to the pleural cavity and a reduction in radiation doses to organs at
Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVE
To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM).
METHODS
Twenty-six patients with DMM (23 pleural and three peritoneal), previously untreated, were
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVE
To describe the initial experience at Dana-Farber Cancer Institute/Brigham and Women's Hospital with intensity-modulated radiation therapy (IMRT) as adjuvant therapy after extrapleural pneumonectomy (EPP) and adjuvant chemotherapy.
METHODS
The medical records of patients treated with IMRT
Malignant peritoneal mesothelioma presenting with persistent high fever.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Malignant peritoneal mesothelioma (MPM) is a rare tumor that develops in the peritoneum. In this paper, we describe an extremely rare case of MPM metastasizing to the appendix in a 48-year-old female who initially presented with a persistent high fever. The woman reported a slight lower abdominal
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is resistant to unimodal approaches. Multimodal treatment has provided encouraging results.
METHODS
Phase II, open-label study of the combination of chemotherapy (pemetrexed 500 mg/m²+cisplatin 75 mg/m² IV
Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
We aim to report the outcome of patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy (EPP) and adjuvant hemithoracic radiotherapy with or without chemotherapy at a single Australian institution.
METHODS
Between July 2004 and March 2013, 53 patients were
Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVE
Management of malignant pleural mesothelioma (MPM) has been an important clinical issue regardless of the treatment modality employed. We aimed to investigate the efficacy of oxytetracycline (OT), Corynebacterium parvum (CP), and nitrogen mustard (NM) in the management of pleural effusion
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
